Citi initiated coverage of Gilead (GILD) with a Buy rating and $125 price target The firm says that despite the stock’s near-term ...

Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...

at 06:50 Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow Gilead Sciences, Inc. today presented the first in-depth look at full results from ...

Gilead Sciences has announced new data from its pivotal Phase III PURPOSE 2 trial providing further details on the efficacy, ...

And then at the end of the talk, the presenter actually disclosed that this long-acting integrase inhibitor is being ...

Sure, condoms are still an effective strategy for lowering the risk of sexually transmitted infections (STIs) — but now, they ...

Gilead Sciences, Inc. today announced the presentation of new research data from its innovative HIV treatment portfolio and pipeline, including a broad range of data on investigational and marketed ...

He expressed optimism that this growth will continue, driven by the potential approval of lenacapavir as a preventive ...

Recent health data reveals an alarming rise in HIV transmission rate between older men and young women, presenting a complex ...

What is patent evergreening and what does the Indian patent regime tell us about it? Also, go beyond the nugget to know about ...